Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization

Clinical and Experimental Immunology

Volumn 163, Issue 2, 2011, Pages 165-177

  Nakamoto, Y ^a   Mizukoshi, E ^a   Kitahara, M ^a   Arihara, F ^a   Sakai, Y ^a   Kakinoki, K ^a   Fujita, Y ^a   Marukawa, Y ^a   Arai, K ^a   Yamashita, T ^a   Mukaida, N ^a   Matsushima, K ^b   Matsui, O ^a   Kaneko, S ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dendritic cells; Hepatocellular carcinoma; Immunotherapy; Recurrence free survival; Transcatheter hepatic arterial embolization

Indexed keywords

EOTAXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMING RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; AUTOIMMUNE DISEASE; BLEEDING; BRAIN DISEASE; CELL STIMULATION; CELL TRANSFER; CLINICAL ARTICLE; DENDRITIC CELL; DRUG ACTIVITY; DRUG FEVER; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIVER ABSCESS; LIVER CELL CARCINOMA; MALE; MONOCYTE; MYALGIA; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS C; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-4; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM RECURRENCE, LOCAL; PICIBANIL;

EID: 78650802118     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04246.x     Document Type: Article

References (60)

1. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127:S159-66.
2. Belghiti J. Resection and liver transplantation for HCC. J Gastroenterol 2009; 44 (Suppl. 19):132-5.
3. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188:341-50.
4. Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003; 237:536-43.
5. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11.
6. Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008; 99:363-407.
7. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
8. Lemos MP, Esquivel F, Scott P, Laufer TM. MHC class II expression restricted to CD8alpha+ and CD11b+ dendritic cells is sufficient for control of Leishmania major. J Exp Med 2004; 199:725-30.
9. Ni K, O'Neill HC. The role of dendritic cells in T cell activation. Immunol Cell Biol 1997; 75:223-30.
10. Andrews DM, Andoniou CE, Scalzo AA et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol 2005; 42:547-55.
11. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109:409-17.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
13. Forster R, Schubel A, Breitfeld D et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99:23-33.
14. MartIn-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198:615-21.
15. Ratzinger G, Stoitzner P, Ebner S et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 2002; 168:4361-71.
16. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003; 63:4112-18.
17. Okamoto M, Oshikawa T, Tano T et al. Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 2006; 29:78-86.
18. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6.
19. Hill KS, Errington F, Steele LP et al. OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J Immunol 2008; 181:3108-15.
20. Nakamoto Y, Mizukoshi E, Tsuji H et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 2007; 147:296-305.
21. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26.
22. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802.
23. Makuuchi M. General rules for the clinical and pathological study of primary liver cancer, 2nd edn. Tokyo: Kanehara & Co., Ltd, 2003.
24. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16:661-9.
25. Dhodapkar MV, Steinman RM, Sapp M et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104:173-80.
26. Orange JS, Brodeur SR, Jain A et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002; 109:1501-9.
27. Klausner RD, Donaldson JG, Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 1992; 116:1071-80.
28. Mizukoshi E, Nakamoto Y, Marukawa Y et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006; 43:1284-94.
29. Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 2006; 118:1194-204.
30. Mizukoshi E, Honda M, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. J Hepatol 2008; 49:946-54.
31. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-49.
32. Itoh T, Ueda Y, Okugawa K et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother 2003; 52:207-14.
33. Kuroki H, Morisaki T, Matsumoto K et al. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 2003; 52:561-8.
34. Gunn MD, Kyuwa S, Tam C et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189:451-60.
35. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. HLA 1991, Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Tokyo: Oxford University Press, 1992.
36. Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8.
37. Chrzanowska A, Krawczyk M, Baranczyk-Kuzma A. Changes in arginase isoenzymes pattern in human hepatocellular carcinoma. Biochem Biophys Res Commun 2008; 377:337-40.
38. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009; 44 (Suppl. 19):96-101.
39. Okamoto M, Oshikawa T, Tano T et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 2003; 95:316-26.
40. Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001; 166:5407-15.
41. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002; 168:1831-9.
42. Nicolas A, Cathelin D, Larmonier N et al. Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. J Immunol 2007; 179:812-18.
43. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-51.
44. West E, Morgan R, Scott K et al. Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immunother 2009; 32:66-78.
45. Hirooka Y, Itoh A, Kawashima H et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas 2009; 38:e69-74.
46. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:372-83.
47. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73.
48. Ayaru L, Pereira SP, Alisa A et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 2007; 178:1914-22.
49. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78.
50. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61:6451-8.
51. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58:1-14.
52. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39:73-80.
53. Sugamura K, Asao H, Kondo M et al. The common gamma-chain for multiple cytokine receptors. Adv Immunol 1995; 59:225-77.
54. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998; 188:1307-20.
55. McMillan SJ, Bishop B, Townsend MJ, McKenzie AN, Lloyd CM. The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 2002; 195:51-7.
56. de Saint-Vis B, Fugier-Vivier I, Massacrier C et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160:1666-76.
57. Shanmugham LN, Petrarca C, Frydas S et al. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. J Exp Clin Cancer Res 2006; 25:529-36.
58. Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol 2004; 23:549-60.
59. Simson L, Ellyard JI, Dent LA et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007; 178:4222-9.
60. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001; 2:1126-32.